| Gene symbol | STAT3 | Synonyms | ADMIO, ADMIO1, APRF, HIES | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | signal transducer and activator of transcription 3 | ||||
| Gene symbol | TLR9 | Synonyms | CD289 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3p21.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | toll like receptor 9 | ||||
| GTO ID | GTC2747 |
| Trial ID | NCT04995536 |
| Disease | Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | TLR9|STAT3 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | CpG-STAT3 siRNA CAS3/SS3 |
| Co-treatment | Radiation Therapy |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Study of Intratumoral Injections of CpG-STAT3 siRNA (CAS3/SS3) in Combination With Local Radiation in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL) |
| Year | 2023 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 20589|NCI-2021-06965|20589|P30CA033572|P50CA107399|Scopus Biopharma |
| Cohort 1 | |||||||
|
|||||||